Julian Harrison
Stock Analyst at BTIG
(4.61)
# 212
Out of 5,142 analysts
92
Total ratings
60%
Success rate
22.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Reiterates: Buy | $70 | $44.18 | +58.44% | 5 | Feb 20, 2026 | |
| ARDX Ardelyx | Reiterates: Buy | $17 | $5.75 | +195.65% | 3 | Feb 20, 2026 | |
| INVA Innoviva | Initiates: Buy | $35 | $23.41 | +49.51% | 1 | Feb 17, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $118 → $151 | $73.62 | +105.11% | 4 | Feb 10, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Buy | $24 | $18.68 | +28.48% | 4 | Feb 9, 2026 | |
| TBPH Theravance Biopharma | Reiterates: Buy | $40 | $19.26 | +107.68% | 4 | Feb 3, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $37 → $46 | $45.54 | +1.01% | 4 | Jan 16, 2026 | |
| MREO Mereo BioPharma Group | Reiterates: Buy | $1 | $0.40 | +148.39% | 3 | Jan 16, 2026 | |
| LQDA Liquidia | Reiterates: Buy | $49 | $32.74 | +49.66% | 6 | Jan 13, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $63 → $73 | $33.32 | +119.09% | 4 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $150 | $132.91 | +12.86% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.20 | +56.25% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $137 | $69.91 | +95.97% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.21 | +313.22% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $13.99 | +171.62% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $6.98 | +530.37% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.63 | +280.23% | 2 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $28.07 | +117.31% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $86.59 | -5.30% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $5.82 | +37.46% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $3.73 | +302.14% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $14.04 | +99.43% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $14.80 | +170.27% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.71 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $54.29 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.40 | +2,150.00% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $3.25 | +146.15% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.60 | +1,241.38% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.61 | +24,490.16% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $474.52 | - | 2 | Feb 11, 2022 |
Spyre Therapeutics
Feb 20, 2026
Reiterates: Buy
Price Target: $70
Current: $44.18
Upside: +58.44%
Ardelyx
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $5.75
Upside: +195.65%
Innoviva
Feb 17, 2026
Initiates: Buy
Price Target: $35
Current: $23.41
Upside: +49.51%
Nektar Therapeutics
Feb 10, 2026
Maintains: Buy
Price Target: $118 → $151
Current: $73.62
Upside: +105.11%
MoonLake Immunotherapeutics
Feb 9, 2026
Reiterates: Buy
Price Target: $24
Current: $18.68
Upside: +28.48%
Theravance Biopharma
Feb 3, 2026
Reiterates: Buy
Price Target: $40
Current: $19.26
Upside: +107.68%
Maze Therapeutics
Jan 16, 2026
Maintains: Buy
Price Target: $37 → $46
Current: $45.54
Upside: +1.01%
Mereo BioPharma Group
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.40
Upside: +148.39%
Liquidia
Jan 13, 2026
Reiterates: Buy
Price Target: $49
Current: $32.74
Upside: +49.66%
Oruka Therapeutics
Jan 12, 2026
Maintains: Buy
Price Target: $63 → $73
Current: $33.32
Upside: +119.09%
Jan 8, 2026
Maintains: Buy
Price Target: $120 → $150
Current: $132.91
Upside: +12.86%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $3.20
Upside: +56.25%
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $137
Current: $69.91
Upside: +95.97%
Dec 2, 2025
Reiterates: Buy
Price Target: $5
Current: $1.21
Upside: +313.22%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $13.99
Upside: +171.62%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.98
Upside: +530.37%
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.63
Upside: +280.23%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $28.07
Upside: +117.31%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $86.59
Upside: -5.30%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $5.82
Upside: +37.46%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $3.73
Upside: +302.14%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $14.04
Upside: +99.43%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $14.80
Upside: +170.27%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $15.71
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $54.29
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.40
Upside: +2,150.00%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.25
Upside: +146.15%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.60
Upside: +1,241.38%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.61
Upside: +24,490.16%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $474.52
Upside: -